Cosentyx provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show

Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg. Data at 2 years demonstrate over 50% of adults with active PsA achieved ACR50, and almost 50% achieved PASI 100 response with Cosentyx 300mg   -   Results strengthen unique position of Cosentyx as a rapid and long-lasting comprehensive treatment of spondyloarthritis and psoriatic disease, with over 200,000 patients treated worldwide Basel, June 12, 2019 - Novartis, a global leader in rheumatology and immuno-dermatology, announced today new data from the FUTURE 5 trial showing no radiographic progression (mTSS 0.5) in almost 90% of psoriatic arthritis (PsA) patients treated with Cosentyx (secukinumab) 300mg over 2 years. "Half of patients with psoriatic arthritis experience bone erosion within approximately two years. Left untreated, this can lead to irreversible joint damage and disability, having a substantial impact on quality of life," said Dr. Philip J. Mease, Director of Rheumatology Research, Swedish Medical Center/Providence St Joseph Health and Clinical Professor, University of Washington School of Medicine, Seattle, WA. "The availability of a treatment that is proven to inhibit progression of psoriatic arthritis through two years gives physicians and patients more choice in the management of this debilitating condition." The trial investigated the effect of Cosentyx on the signs and symptoms of PsA, in addition to inhibition of radiographic progression of PsA.